Related Experiment Video
Updated: May 16, 2026

A High-throughput Shigella-specific Bactericidal Assay
Published on: February 27, 2019
[Acute intestinal infections: current and upcoming vaccines]
Paul Erlich1, Philippe J Sansonetti
1Institut Pasteur, unité de pathogénie microbienne moléculaire, 75724 Paris cedex 15, France.
Abstract:
Currently, only a few licensed vaccines against intestinal infections are available. Existing vaccines have shown good efficacy when used by travelers in industrialized countries. However, these vaccines have lower efficacy in endemic areas with high prevalence of enteric pathogens. Current vaccines are too expensive to be efficiently distributed in endemic countries. Immune correlates of protection are not well defined for current licensed vaccines. A better understanding of protection mechanisms at the intestinal mucosal surfaces should allow the development of more efficient vaccines. Gut physiology and microbial composition play an important role in both physical integrity and immunological status of the gastro-intestinal tract. These parameters can partially explain the disparities observed in current vaccines efficiency. Several next-generation vaccines combined or not with adjuvant able to promote a strong mucosal response in the intestine, are under preclinical and clinical investigations.
Related Concept Videos
Vaccinations
Microorganisms in Medicine and Therapeutics
Bacterial Gastroenteritis
Vaccines
Acute Pyelonephritis I: Introduction
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

